RadioMedix is a clinical-stage biotechnology company focused on targeted radiopharmaceuticals for diagnosis, monitoring, and therapy of cancer. Its lead therapeutic program is AlphaMedix™ (212Pb‑DOTAMTATE), a lead-212 labelled somatostatin analogue targeted alpha therapy (TAT) agent currently in a Phase II trial initiated in late 2021 for metastatic or inoperable somatostatin-expressing neuroendocrine tumors. The company also markets Detectnet® (64Cu‑DOTATATE), an FDA‑approved diagnostic PET agent (approved September 2020), and is developing additional theranostic agents for brain tumors and pancreatic ductal adenocarcinoma. RadioMedix operates contract service, preclinical and cGMP manufacturing facilities at its Spica Center in Humble, Texas to support clinical trials and commercialization. The company announced a $40 million Series A equity financing to advance its Targeted Alpha Therapy platform and diagnostic companion radiopharmaceuticals. RadioMedix additionally provides a drug discovery center and pre-clinical core facility for early probe development and in vitro/in vivo evaluation.

Total raised

$40M

Funding rounds

1

Latest round

Series A

Latest activity

Oct 2022